Replies to post #424095 on Amarin Corp Plc (AMRN)

[JRoon71]

Honestly, I don't think one has anything do with the other. The sales/distribution methods in Europe are much different than Canada and the US.

I agree, Vascepa has been a bit of a disappointment in Canada. $17-18M in full-year revenue after this many years is pretty disappointing. I wasn't able to listen to the earnings call today, but am hoping to listen to the replay when available.

I think a lot of this goes back to the GIA strategy. HLS is not a big company. They are tiny, and they are boot-strapping it (hence, why they brought in Pfizer originally).

Vascepa in the hands of a BP probably would have gone much differently.

[rosemountbomber]

Not necessarily. What this highlights is the poor return of partnerships. I believe JT mentioned this dynamic when considering partnerships in the EU. V just becomes one out of a hundred other drugs in the salesperson’s bag. Plus they will usually focus their efforts on pushing the drugs that are most profitable to their company. Only way BP really pushes V is if they own it.